LLY
New deal, same Lilly energy
Eli Lilly is back in deal mode, this time agreeing to acquire Kelonia Therapeutics, a clinical-stage biotech working on in vivo gene delivery. Translation: Lilly wants a bigger toolbox for turning cells into little drug factories without making patients go through the usual sci-fi-sounding cell-manufacturing dance outside the body.
Why Kelonia matters
Kelonia’s lead program, KLN-1010, is a lentiviral in vivo CAR-T therapy for relapsed/refractory multiple myeloma, and it’s already in Phase 1. The company also had its data featured in the 2025 ASH Annual Meeting plenary session, which is biotech’s version of getting the good seat on the stage.
That matters for Lilly because this isn’t just a random bolt-on. The deal gives Lilly access to technology that could be used more broadly across genetic medicine, which is the kind of platform pitch Wall Street tends to salivate over when it’s attached to a giant cash-rich pharma name.
Big picture
Lilly has spent plenty of time owning the obesity-and-diabetes conversation, but this acquisition says it wants more than one growth engine humming in the garage. If the science keeps cooperating, this could be one more way for Lilly to turn its balance sheet into future blockbuster optionality.
Big picture: when a mega-cap pharma starts buying platform biotech tech, it’s usually because it thinks the next decade is hiding in the lab coat pocket.